Toxicology Drug Screening Market Size, Share, Growth, and Industry Analysis, By Type (Cardiovascular Disease Drug Screening, Obesity Drug Screening, Diabetes Drug Screening, Others), By Application (Hospitals, Clinics, Laboratory, Others), Regional Insights and Forecast to 2035

Toxicology Drug Screening Market Overview

Toxicology Drug Screening Market size is anticipated to be worth USD 741.79 million in 2026 and is expected to reach USD 1835.74 million by 2035 at a CAGR of 10.6%.

The Toxicology Drug Screening Market is expanding steadily as healthcare providers, forensic laboratories, workplace safety programs, rehabilitation centers, and law enforcement agencies increase the adoption of rapid and laboratory-based drug testing solutions. Growing awareness regarding substance abuse monitoring, strict workplace compliance policies, and improved analytical technologies are strengthening demand across developed and emerging economies. More than 72% of hospitals and diagnostic laboratories now integrate automated toxicology analyzers into routine clinical workflows, while over 68% of occupational health providers conduct pre-employment and random drug screening programs. Immunoassay-based screening accounts for nearly 61% of initial testing procedures because of its speed and cost efficiency, whereas confirmatory chromatography-based testing contributes approximately 39% of advanced laboratory analysis.

The United States remains the largest contributor to the Toxicology Drug Screening Market due to widespread workplace testing regulations, advanced healthcare infrastructure, and extensive forensic laboratory networks. More than 80% of federal workplaces maintain mandatory drug testing programs, while nearly 67% of large private employers conduct routine employee screening. Approximately 74% of emergency departments utilize toxicology screening during suspected overdose cases, and over 69% of accredited clinical laboratories operate fully automated drug testing platforms. More than 60% of rehabilitation facilities include toxicology monitoring throughout treatment programs. The increasing prevalence of synthetic opioids and polysubstance abuse has encouraged hospitals to expand testing panels by nearly 48%, supporting continuous innovation and broader adoption of laboratory and point-of-care toxicology screening technologies across the country.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 74% of healthcare facilities increased toxicology screening capacity, while approximately 69% of employers strengthened workplace drug testing programs and over 63% of emergency departments expanded rapid screening protocols to improve patient management and workplace compliance.
• Major Market Restraint: Around 46% of laboratories report high confirmatory testing costs, nearly 41% experience reimbursement limitations, about 38% face sample handling complexities, and approximately 35% encounter challenges related to false-positive screening outcomes requiring additional verification.
• Emerging Trends: Nearly 66% of laboratories are adopting automated analyzers, about 59% are integrating multiplex drug panels, approximately 52% utilize artificial intelligence-assisted interpretation, and over 48% are implementing digital laboratory information management systems for workflow optimization.
• Regional Leadership: North America contributes approximately 42% of overall market activity, Europe accounts for nearly 28%, Asia-Pacific represents around 22%, while Latin America and the Middle East & Africa collectively contribute nearly 8% of toxicology drug screening demand.
• Competitive Landscape: Around 64% of market competition focuses on automated laboratory systems, nearly 58% targets rapid point-of-care testing, approximately 49% emphasizes expanded testing menus, while over 45% prioritizes laboratory workflow efficiency and integrated diagnostic platforms.
• Market Segmentation: Laboratory-based screening represents nearly 62% of testing procedures, point-of-care testing contributes approximately 38%, workplace applications account for about 36%, clinical diagnostics represent around 34%, while forensic testing contributes nearly 30% of total demand.
• Recent Development: Approximately 57% of newly introduced toxicology platforms support expanded multi-drug detection panels, about 53% feature automation upgrades, nearly 47% incorporate digital reporting capabilities, and over 44% improve analytical sensitivity for emerging synthetic substances.

Toxicology Drug Screening Market Latest Trends

The Toxicology Drug Screening Market is experiencing rapid technological transformation as laboratories increasingly adopt automation, multiplex testing, and digital reporting systems. Nearly 66% of diagnostic laboratories now use automated analyzers to improve sample throughput, while approximately 59% have expanded testing panels capable of identifying more than 15 drug classes in a single analysis. Point-of-care testing contributes close to 38% of screening procedures, helping emergency departments and occupational health centers deliver faster clinical decisions. These developments continue to strengthen the Toxicology Drug Screening Market Report and Toxicology Drug Screening Market Analysis.

Another important trend is the growing use of high-sensitivity confirmatory technologies for detecting synthetic opioids, designer drugs, and prescription medication misuse. Around 54% of healthcare facilities have upgraded laboratory information systems to improve workflow efficiency, while nearly 49% are integrating electronic reporting platforms with hospital networks. More than 45% of toxicology laboratories have increased investments in artificial intelligence-assisted interpretation, improving result consistency and laboratory productivity while supporting Toxicology Drug Screening Market Growth, Market Trends, Market Outlook, and Market Opportunities.

Toxicology Drug Screening Market Dynamics

DRIVER

"Rising demand for workplace and clinical drug testing"

The primary growth driver for the Toxicology Drug Screening Market is the increasing requirement for workplace safety programs, hospital diagnostics, and substance abuse monitoring. More than 70% of large employers conduct pre-employment or random drug testing, while nearly 65% of industrial organizations have strengthened workplace compliance initiatives. Around 74% of emergency departments routinely perform toxicology screening for suspected overdose, poisoning, or unexplained neurological symptoms. Clinical laboratories report that approximately 62% of toxicology requests involve multi-drug screening panels, reflecting the growing prevalence of polysubstance exposure. More than 58% of rehabilitation centers perform scheduled toxicology testing throughout treatment programs to improve patient monitoring. Advances in immunoassay screening and chromatography-based confirmation have increased laboratory efficiency by nearly 45%, reducing turnaround times and improving diagnostic confidence. Rising awareness regarding opioid misuse, synthetic narcotics, prescription drug abuse, and occupational safety regulations continues to support the Toxicology Drug Screening Market Report, Market Research Report, Industry Analysis, Market Forecast, Market Share, and Market Insights.

RESTRAINTS

"High costs of confirmatory testing and operational complexity"

One of the major restraints affecting the Toxicology Drug Screening Market is the high operational cost associated with advanced confirmatory testing technologies. Nearly 46% of laboratories identify expensive analytical instruments and maintenance requirements as significant barriers to expansion. Approximately 41% of healthcare providers experience reimbursement limitations for comprehensive toxicology testing, reducing accessibility for smaller facilities. Around 39% of laboratories report increased expenditure on quality assurance, calibration, and regulatory compliance. False-positive screening outcomes affect nearly 18% of initial immunoassay results, requiring additional confirmatory testing that extends laboratory workload. More than 35% of diagnostic centers face shortages of highly trained laboratory professionals capable of operating sophisticated analytical equipment. Approximately 33% of facilities experience workflow delays caused by increasing sample volumes and regulatory documentation. These limitations reduce testing efficiency for smaller laboratories despite growing clinical demand, creating challenges for broader adoption within the Toxicology Drug Screening Market Industry Report and Toxicology Drug Screening Market Analysis.

OPPORTUNITY

"Expansion of point-of-care and multiplex testing technologies"

The Toxicology Drug Screening Market offers significant opportunities through the expansion of rapid point-of-care diagnostics and multiplex toxicology platforms. Nearly 60% of healthcare institutions are increasing investments in portable drug screening systems that deliver results within minutes. Approximately 55% of hospitals plan to expand emergency department testing capabilities through integrated point-of-care devices. More than 52% of diagnostic laboratories are introducing multiplex panels capable of identifying over 20 drug categories simultaneously, improving clinical efficiency and reducing repeat testing. Around 48% of rehabilitation facilities are adopting digital patient monitoring systems linked with toxicology reporting software. Approximately 44% of forensic laboratories are modernizing analytical workflows using automated sample preparation and artificial intelligence-assisted interpretation. Increasing adoption across occupational health services, correctional facilities, sports organizations, and roadside testing programs continues to generate long-term opportunities. These developments strengthen Toxicology Drug Screening Market Opportunities, Market Outlook, Market Growth, Industry Analysis, Market Forecast, and Market Research Report.

CHALLENGE

"Rapid emergence of new synthetic drugs and evolving regulations"

The biggest challenge for the Toxicology Drug Screening Market is keeping pace with the continuous emergence of synthetic drugs and changing regulatory requirements. Nearly 43% of toxicology laboratories update their testing panels frequently to detect newly identified psychoactive substances. Approximately 40% of healthcare providers report difficulties identifying designer drugs using conventional screening methods. Around 37% of laboratories face increasing validation requirements before introducing expanded testing panels, while nearly 35% experience delays associated with accreditation and regulatory approvals. More than 31% of forensic laboratories require continuous staff training to maintain analytical accuracy for new substances. Approximately 29% of diagnostic centers report compatibility issues when integrating modern toxicology software with existing laboratory infrastructure. Maintaining high analytical sensitivity while controlling operational costs remains a major challenge for laboratories worldwide. Addressing these issues will remain essential for sustaining Toxicology Drug Screening Market Share, Market Insights, Market Trends, Market Growth, and Industry Report performance.

Toxicology Drug Screening Market Segmentation

The Toxicology Drug Screening Market is segmented by type and application to address different therapeutic research needs and end-user requirements. By type, cardiovascular disease drug screening accounts for approximately 34% of overall demand, followed by obesity drug screening with nearly 24%, diabetes drug screening with about 22%, and other drug screening applications contributing close to 20%. By application, laboratories hold nearly 39% of utilization, hospitals account for around 31%, clinics contribute approximately 21%, while other applications represent nearly 9%. Increasing adoption of automated screening technologies, high-throughput analytical platforms, and biomarker-based toxicity assessment continues to strengthen market expansion across every segment.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Cardiovascular Disease Drug Screening: Cardiovascular disease drug screening represents the largest segment of the Toxicology Drug Screening Market, accounting for approximately 34% of total screening activity. Pharmaceutical companies continue to prioritize cardiovascular safety because nearly every newly developed therapeutic candidate requires extensive cardiotoxicity assessment before clinical progression. More than 72% of preclinical toxicology studies include cardiovascular biomarker analysis, while around 65% incorporate electrophysiological safety evaluations to identify adverse cardiac effects. Approximately 58% of contract research organizations utilize automated high-throughput screening systems for cardiovascular toxicity assessment, significantly increasing testing efficiency. Nearly 49% of laboratory workflows now integrate cell-based assays for early toxicity detection before animal studies. 

Obesity Drug Screening: Obesity drug screening contributes nearly 24% of the Toxicology Drug Screening Market as pharmaceutical developers increase research targeting metabolic disorders. More than 61% of obesity drug discovery programs include toxicological screening during the earliest phases of candidate selection to minimize development failures. Approximately 57% of metabolic drug studies evaluate liver toxicity because hepatic complications remain one of the primary safety concerns. Around 52% of research organizations employ automated screening technologies capable of processing thousands of compounds each week. Nearly 46% of obesity drug candidates undergo additional endocrine toxicity assessments to evaluate hormonal balance and metabolic stability. 

Diabetes Drug Screening: Diabetes drug screening accounts for approximately 22% of the Toxicology Drug Screening Market as global pharmaceutical research increasingly focuses on improving treatment safety for metabolic disorders. Nearly 64% of diabetes drug development programs include repeated toxicology assessments to evaluate kidney, liver, pancreatic, and cardiovascular safety. Around 56% of screening laboratories use automated biochemical analyzers to measure toxicity biomarkers with greater consistency. Approximately 48% of drug candidates undergo long-term toxicity evaluations before advancing to clinical investigation.

Others: The others segment represents approximately 20% of the Toxicology Drug Screening Market and includes neurological, respiratory, oncology, autoimmune, infectious disease, gastrointestinal, and rare disease drug screening programs. Nearly 59% of pharmaceutical companies conduct specialized toxicology testing for targeted therapies and biologics outside cardiovascular and metabolic diseases. Around 51% of research laboratories increasingly evaluate immunotoxicity, neurotoxicity, and reproductive toxicity during preclinical development. Approximately 47% of advanced laboratories integrate artificial intelligence-assisted screening to improve compound prioritization. Nearly 44% of testing facilities have expanded multiplex biomarker panels capable of detecting multiple toxicological responses simultaneously.

BY APPLICATION

Hospitals: Hospitals account for approximately 31% of the Toxicology Drug Screening Market due to the increasing requirement for rapid diagnosis of poisoning, overdose, adverse drug reactions, and emergency toxicology investigations. Nearly 74% of emergency departments routinely perform toxicology screening for patients with unexplained neurological symptoms, suspected substance abuse, or accidental poisoning. Around 68% of tertiary care hospitals have fully automated toxicology analyzers integrated into central laboratories. Approximately 57% of intensive care units utilize comprehensive toxicology panels for critical patient monitoring. Nearly 49% of trauma centers conduct immediate drug screening before emergency surgical procedures when clinically indicated. Hospital laboratories increasingly employ multiplex testing capable of identifying more than 20 drug classes from a single specimen. Continuous improvements in laboratory automation and electronic medical record integration have enhanced diagnostic efficiency by approximately 46%. 

Clinics: Clinics contribute approximately 21% of the Toxicology Drug Screening Market by providing convenient drug testing services for outpatient diagnosis, rehabilitation monitoring, occupational health, and chronic disease management. Nearly 63% of specialty clinics perform routine toxicology screening for pain management patients receiving long-term prescription therapies. Around 55% of addiction treatment centers use scheduled toxicology monitoring throughout rehabilitation programs to improve treatment adherence. Approximately 48% of occupational health clinics conduct pre-employment and periodic workplace drug screening for safety-sensitive occupations. Nearly 43% of outpatient facilities have adopted rapid point-of-care toxicology testing systems capable of producing results within minutes. Digital reporting platforms are now utilized by approximately 46% of clinics to improve workflow efficiency and patient record management.

Laboratory: Laboratories represent the largest application segment with approximately 39% of total Toxicology Drug Screening Market demand because they perform confirmatory analysis, high-volume screening, forensic investigations, and pharmaceutical safety studies. More than 76% of reference laboratories utilize automated sample preparation systems to improve productivity and analytical consistency. Around 67% employ liquid chromatography or mass spectrometry technologies for confirmatory toxicology testing. Approximately 61% of laboratory testing involves multi-drug panels capable of detecting prescription medicines, illicit substances, and emerging synthetic compounds. Nearly 53% of laboratories have integrated laboratory information management systems that automate reporting and quality control. About 47% utilize artificial intelligence-supported data interpretation for faster analytical review. 

Others: The others application segment contributes approximately 9% of the Toxicology Drug Screening Market and includes forensic laboratories, law enforcement agencies, sports organizations, military institutions, correctional facilities, educational institutions, and workplace compliance programs. Nearly 58% of forensic investigations require toxicological analysis to support legal proceedings. Around 52% of correctional institutions perform routine drug screening to improve safety and rehabilitation outcomes. Approximately 45% of sports organizations conduct anti-doping toxicology testing for athlete compliance programs. Nearly 41% of transportation companies include periodic drug testing within employee safety initiatives. 

Toxicology Drug Screening Market Regional Outlook

The Toxicology Drug Screening Market demonstrates strong regional diversification supported by expanding pharmaceutical research, hospital diagnostics, forensic testing, and workplace drug screening programs. North America accounts for approximately 42% of the global market share due to advanced laboratory infrastructure and strict regulatory compliance. Europe contributes nearly 28% through increasing pharmaceutical innovation and clinical toxicology research. Asia-Pacific represents around 22% as healthcare investments, contract research activities, and diagnostic laboratory expansion accelerate. The Middle East & Africa collectively hold approximately 8% of the global market, supported by growing healthcare modernization and public safety initiatives. Across all regions, more than 67% of laboratories are increasing automation, nearly 59% are expanding multi-drug testing panels, while approximately 48% continue investing in digital laboratory information systems to improve testing efficiency and reporting accuracy.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for approximately 42% of the Toxicology Drug Screening Market, making it the largest regional contributor. More than 82% of major hospitals operate advanced toxicology laboratories equipped with automated screening systems, while approximately 76% of workplace drug testing programs utilize standardized laboratory protocols. Nearly 71% of emergency departments routinely perform toxicology analysis for overdose and poisoning cases. Around 68% of pharmaceutical safety studies conducted in the region include comprehensive toxicological assessments before clinical development. More than 63% of forensic laboratories have adopted high-throughput analytical platforms capable of processing thousands of samples every month. Approximately 57% of rehabilitation centers integrate scheduled toxicology testing into patient monitoring programs. Digital laboratory information systems are used by nearly 54% of diagnostic facilities, improving operational efficiency and reporting accuracy. 

EUROPE

Europe represents approximately 28% of the Toxicology Drug Screening Market and continues to benefit from advanced healthcare systems, pharmaceutical innovation, and stringent regulatory standards. Around 72% of pharmaceutical manufacturers perform comprehensive toxicology assessments during early-stage drug development. Nearly 66% of hospital laboratories utilize automated immunoassay screening technologies supported by confirmatory chromatography-based testing. Approximately 61% of forensic institutions continue expanding analytical capabilities for detecting synthetic drugs and prescription medication misuse. More than 56% of clinical laboratories have integrated digital workflow management systems that reduce reporting time and improve analytical quality. Around 49% of occupational health providers conduct routine workplace drug testing for safety-sensitive industries. Toxicology research involving biological therapies, precision medicine, and personalized treatment programs continues to increase across the region. Growing investments in laboratory modernization, diagnostic innovation, and clinical research infrastructure strengthen Europe's position as the second-largest contributor to the Toxicology Drug Screening Market.

ASIA-PACIFIC

Asia-Pacific contributes approximately 22% of the Toxicology Drug Screening Market and remains the fastest expanding regional landscape due to rising healthcare investments and pharmaceutical manufacturing activities. More than 69% of newly established diagnostic laboratories have introduced automated toxicology analyzers to increase testing capacity. Approximately 64% of contract research organizations perform toxicology screening for international pharmaceutical companies developing new drug candidates. Nearly 58% of tertiary hospitals continue expanding emergency toxicology services to manage increasing poisoning and overdose cases. Around 52% of laboratory facilities are investing in high-throughput analytical technologies and digital reporting systems. More than 47% of pharmaceutical research organizations have strengthened preclinical safety testing capabilities using advanced biomarker analysis. 

MIDDLE EAST & AFRICA

The Middle East & Africa account for approximately 8% of the Toxicology Drug Screening Market and continue to demonstrate steady adoption of advanced diagnostic technologies. Around 57% of tertiary hospitals have expanded toxicology laboratory services to improve emergency care and poisoning management. Approximately 49% of government healthcare institutions continue investing in modern laboratory equipment supporting forensic investigations and public health surveillance. Nearly 45% of occupational health providers have strengthened workplace drug screening programs for industrial sectors. Around 41% of diagnostic laboratories utilize automated screening platforms capable of improving laboratory productivity and analytical consistency. More than 38% of healthcare organizations have implemented electronic laboratory reporting systems that enhance workflow efficiency. Expanding healthcare infrastructure, increased public safety initiatives, improved laboratory accreditation standards, and growing pharmaceutical research activities continue strengthening the region's contribution to the Toxicology Drug Screening Market.

List of Key Toxicology Drug Screening Market Companies

• Thermo Fisher Scientific Inc.
• Merck
• Bio-Rad Laboratories Inc.
• Danaher
• Charles River Laboratories International Inc.
• Enzo Life Sciences Inc.
• Eurofins Scientific
• Selvita
• Laboratory Corporation of America Holdings
• Promega Corporation
• The Jackson Laboratory
• Agilent Technologies, Inc.
• Waters
• TECHCOMP GROUP
• Wuxi AppTec

Top Two Companies with Highest Share

• Thermo Fisher Scientific Inc.: Approximately 18% market share supported by extensive toxicology instruments, laboratory automation, and broad pharmaceutical testing capabilities.
• Danaher: Approximately 14% market share driven by advanced life science platforms, diagnostic technologies, and high laboratory adoption across pharmaceutical and clinical research.

Investment Analysis and Opportunities

Investment activity in the Toxicology Drug Screening Market continues to increase as pharmaceutical manufacturers, diagnostic laboratories, and contract research organizations expand analytical capabilities. Nearly 64% of new investments focus on laboratory automation to improve testing efficiency and reduce turnaround time. Around 58% of capital expenditure supports high-throughput analytical platforms capable of processing significantly larger sample volumes. Approximately 53% of research organizations continue investing in biomarker discovery and multiplex toxicology assays that improve compound safety evaluation. Nearly 49% of laboratory expansion projects include artificial intelligence-assisted data interpretation and digital laboratory information systems. Increasing regulatory requirements and pharmaceutical innovation continue supporting long-term investment opportunities.

Market opportunities remain strong across clinical diagnostics, forensic toxicology, workplace screening, and pharmaceutical safety testing. Around 61% of biotechnology companies are increasing investment in advanced toxicological assessment before clinical studies. Approximately 56% of contract research organizations continue expanding laboratory capacity to support global pharmaceutical outsourcing. Nearly 51% of diagnostic providers are investing in portable point-of-care screening technologies that improve emergency healthcare delivery. Around 46% of healthcare institutions continue upgrading automated laboratory systems to improve analytical consistency. These developments create attractive opportunities for manufacturers supplying analytical instruments, laboratory software, toxicology reagents, and integrated testing platforms.

New Products Development

Product innovation within the Toxicology Drug Screening Market is increasingly focused on automation, multiplex analysis, and rapid detection technologies. Approximately 62% of newly introduced toxicology systems support simultaneous detection of more than twenty drug categories from a single specimen. Around 57% of new analytical platforms feature automated sample preparation that reduces manual intervention and improves laboratory productivity. Nearly 52% of recently developed testing systems incorporate cloud-enabled reporting functions for faster clinical communication. Approximately 48% of manufacturers have introduced compact analyzers suitable for hospital emergency departments and decentralized diagnostic facilities.

Manufacturers are also strengthening product portfolios by integrating artificial intelligence, digital workflow management, and advanced biomarker analysis. Nearly 55% of newly developed laboratory software platforms include automated quality control monitoring and result interpretation. Around 49% of innovative toxicology assays improve sensitivity for synthetic opioids and designer drugs. Approximately 45% of diagnostic companies are expanding reagent portfolios for multiplex toxicology applications, while nearly 42% are developing portable screening devices supporting workplace, forensic, and clinical testing environments. Continuous technological improvements remain a major competitive strategy throughout the market.

Five Recent Developments

• Thermo Fisher Scientific expanded its automated toxicology testing workflow in 2025 by improving analytical throughput by approximately 32% while reducing manual sample preparation by nearly 40%, enabling higher laboratory productivity and more consistent toxicology screening performance.

• Danaher introduced enhanced laboratory automation capabilities in 2025 that increased processing efficiency by approximately 29% and improved analytical reproducibility by nearly 26% for pharmaceutical toxicology laboratories conducting high-volume screening activities.

• Eurofins Scientific expanded toxicology laboratory services in 2025 by increasing multi-drug testing capacity by approximately 35% while improving digital reporting efficiency by nearly 31%, supporting pharmaceutical research and forensic testing applications.

• Agilent Technologies introduced upgraded chromatography solutions in 2025 capable of improving toxicology detection sensitivity by approximately 28% while reducing analytical processing time by nearly 24% across advanced laboratory environments.

• Waters strengthened its toxicology analytical portfolio in 2025 by enhancing mass spectrometry performance with approximately 27% higher analytical precision and nearly 23% faster data processing for complex toxicological investigations.

Report Coverage Of Toxicology Drug Screening Market

The Toxicology Drug Screening Market report provides comprehensive analysis covering market size, market share, industry trends, competitive landscape, technology developments, application analysis, regional outlook, investment opportunities, and strategic business developments. The report evaluates more than 15 leading manufacturers, analyzes four major application categories and four product segments, while covering approximately 100% of the global market distribution across North America, Europe, Asia-Pacific, and the Middle East & Africa.

The report further examines technological innovation, laboratory automation, pharmaceutical toxicology research, forensic applications, workplace screening, and healthcare diagnostics. Approximately 67% of the analysis focuses on laboratory modernization, around 58% evaluates pharmaceutical safety testing trends, nearly 49% reviews emerging diagnostic technologies, while approximately 43% assesses competitive positioning, investment opportunities, product innovation, and future market expansion strategies supporting informed business decision-making.

Toxicology Drug Screening Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 741.79 Billion in 2026
Market Size Value By	USD 1835.74 Billion by 2035
Growth Rate	CAGR of 10.6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Cardiovascular Disease Drug Screening Obesity Drug Screening Diabetes Drug Screening Others By Application : Hospitals Clinics Laboratory Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample